PACB

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at PacBio (NASDAQ:PACB) and the best and worst performers in the life sciences tools & services industry. The life sciences tools and services sector supports biotech and pharmaceutical R&D and commercialization by providing lab equipment, data analytics, and clinical trial services. These companies benefit from recurring revenue and high margins on specialized products. Looking ahead, the sector is supported by tailwinds like advancements in genomics, personalized medicine, and the use of AI in drug discovery. However, the persistent challenge is dependence on the R&D budgets of large pharmaceutical companies and the volatility of smaller biotech firms. Future headwinds include uncertain research funding and pricing pressures from cost-conscious customers. The 21 life sciences tools & services stocks we track reported a strong Q2. As a group, revenues beat analysts’ consensus estimates by 2.6% while next quarter’s revenue guidance was 0.5% above. Thankfully, share prices of the companies have been resilient as they are up 8.9% on average since the latest earnings results. Pioneering what scientists call "HiFi long-read sequencing," recognized as Nature Methods' method of the year for 2022, Pacific Biosciences (NASDAQ:PACB) develops advanced DNA sequencing systems that enable scientists and researchers to analyze genomes with unprecedented accuracy and completeness. PacBio reported revenues of $39.01 million, down 1.9% year on year. This print fell short of analysts’ expectations by 2.3%. Overall, it was a disappointing quarter for the company with a significant miss of analysts’ EPS estimates. PacBio delivered the weakest performance against analyst estimates of the whole group. Interestingly, the stock is up 3.6% since reporting and currently trades at $1.35. Read our full report on PacBio here, it’s free. Serving as the guardian of some of medicine's most valuable materials, Azenta (NASDAQ:AZTA) provides biological sample management, storage, and genomic services that help pharmaceutical and biotechnology companies preserve and analyze critical research materials. Azenta reported revenues of $161.2 million, up 12% year on year, outperforming analysts’ expectations by 8%. The business had an incredible quarter with a beat of analysts’ EPS estimates. The market seems content with the results as the stock is up 4% since reporting. It currently trades at $31.33. Is now the time to buy Azenta? Access our full analysis of the earnings results here, it’s free. With roots dating back to the pioneering days of nuclear magnetic resonance technology, Bruker (NASDAQ:BRKR) develops and manufactures high-performance scientific instruments that enable researchers and industrial analysts to explore materials at microscopic, molecular, and cellular levels. Bruker reported revenues of $838.5 million, up 5.2% year on year, falling short of analysts’ expectations by 1.9%. It was a slower quarter as it posted a slight miss of analysts’ organic revenue estimates and full-year revenue guidance slightly missing analysts’ expectations. Bruker delivered the weakest full-year guidance update among its peers. As expected, the stock is down 9% since the results and currently trades at $58.50. Read our full analysis of Bruker’s results here. Formerly known as PerkinElmer until its rebranding in 2023, Revvity (NYSE:RVTY) provides health science technologies and services that support the complete workflow from discovery to development and diagnosis to cure. Revvity reported revenues of $711.1 million, up 4.5% year on year. This result surpassed analysts’ expectations by 0.6%. Overall, it was a strong quarter as it also produced a beat of analysts’ EPS estimates and an impressive beat of analysts’ full-year EPS guidance estimates. The stock is up 12.8% since reporting and currently trades at $130. Read our full, actionable report on Revvity here, it’s free. Originally spun off from Hewlett-Packard in 1999 as its measurement and analytical division, Agilent Technologies (NYSE:A) provides analytical instruments, software, services, and consumables for laboratory workflows in life sciences, diagnostics, and applied chemical markets. Agilent reported revenues of $1.88 billion, up 8.1% year on year. This number topped analysts’ expectations by 1.9%. It was a strong quarter as it also recorded an impressive beat of analysts’ organic revenue estimates and a solid beat of analysts’ full-year EPS guidance estimates. Agilent achieved the highest guidance raise in the group. The stock is down 1.6% since reporting and currently trades at $152.53. Read our full, actionable report on Agilent here, it’s free. Over the past year, investors have been forced to repeatedly answer the same question: what is the market’s biggest risk? The answer has changed several times, and each shift has reshaped market leadership. Late in 2025 and early 2026, artificial intelligence became the market’s primary uncertainty. Investors questioned whether AI would erode software pricing power and weaken competitive moats as AI made it easier to replicate once-differentiated products. By the spring, technology took a back seat to geopolitics. The U.S. conflict with Iran briefly became the market’s dominant narrative, raising concerns about oil prices, inflation, and global growth. But as energy markets remained orderly and fears of a prolonged supply disruption faded, investors quickly turned their focus back to fundamentals. Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Growth Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.

A month has gone by since the last earnings report for Pacific Biosciences of California (PACB). Shares have added about 11.6% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Pacific Biosciences due for a pullback? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent catalysts for Pacific Biosciences of California, Inc. before we dive into how investors and analysts have reacted as of late. PacBio reported an adjusted loss per share of 14 cents for the second quarter of 2026, wider than the year-ago adjusted loss of 13 cents per share. The figure came in line with the Zacks Consensus Estimate. The company’s GAAP loss per share was 14 cents in the quarter, flat year over year. PacBio registered total revenues of $39 million, down 2% year over year. The figure missed the Zacks Consensus Estimate by 4.2%. Consumables growth and higher Revio placements were offset by weaker instrument sales and a sharp revenue decline in Asia Pacific. Americas revenues were $17.6 million, down 0.6% year over year. Continued uncertainty surrounding NIH, academic and government funding weighed on capital purchasing, though clinical and commercial customer activity remained resilient. Asia-Pacific revenues totaled $7 million, down 45% year over year. The decrease reflected the completion of a significant population-sequencing program, weaker academic and government demand and lower consumables purchases as customers prepared for the SPRQ-Nx transition. EMEA revenues increased 52% year over year to $14.4 million. Growth was driven by clinical customers moving from pilot programs into routine production, stronger Vega demand and a strategic multi-system Revio placement supporting a national genomics initiative. In the quarter under review, total Product revenues amounted to $32.9 million, down 0.4% from the year-ago quarter. Within the Product segment, Instrument revenues were $12.8 million, down 9.9% year over year. The decline reflected a lower average selling price, including strategic Revio placements at key accounts, and fewer Vega shipments amid academic and government funding constraints. Instrument revenues in the quarter included 20 Revio sequencing systems and 26 Vega sequencing systems. PACB ended the quarter with 366 cumulative Revio system shipments and 200 cumulative Vega system shipments. Consumables revenues for the quarter were $20.1 million, up 6.3% from the prior-year quarter, supported by installed-base expansion and continued Revio utilization. Shipments to clinical customers increased 67% and represented a mid-teens percentage of total consumables shipments. Annualized Revio pull-through per system was approximately $202,000 in the quarter. Growth was partly tempered by customers using existing inventory and validating workflows ahead of broader SPRQ-Nx adoption. Service and other revenues totaled $6.1 million, down 9.4% year over year. In the quarter under review, PacBio’s adjusted gross profit decreased 8.3% year over year to $13.9 million. The adjusted gross margin contracted 200 basis points to 36%. Sales, general and administrative expenses declined 7.7% year over year to $33.4 million. Research and development expenses increased 2.2% year over year to $23 million. Adjusted total operating expenses of $56.1 million decreased 3.4% year over year. Total operating loss was $44.6 million in the reported quarter compared with the prior-year quarter’s $44.9 million. PacBio exited the second quarter of 2026 with cash and investments of $236.9 million compared with $275.9 million at the end of the first quarter of 2026. PacBio reduced its 2026 revenue guidance to $155-$165 million from the prior range of $165-$175 million. The Zacks Consensus Estimate is pegged at $165.8 million. The company now expects an adjusted gross margin of 35%-37%. Adjusted operating expenses are projected at $215-$220 million, down $5 million from the previous guidance range. In the past month, investors have witnessed a downward trend in fresh estimates. The consensus estimate has shifted -8.33% due to these changes. Currently, Pacific Biosciences has a subpar Growth Score of D, however its Momentum Score is doing a lot better with a B. However, the stock has a score of F on the value side, putting it in the lowest quintile for this investment strategy. Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been broadly trending downward for the stock, and the magnitude of this revision indicates a downward shift. It's no surprise Pacific Biosciences has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months. Pacific Biosciences belongs to the Zacks Medical - Instruments industry. Another stock from the same industry, Edwards Lifesciences (EW), has gained 0.5% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026. Edwards Lifesciences reported revenues of $1.74 billion in the last reported quarter, representing a year-over-year change of +13.6%. EPS of $0.78 for the same period compares with $0.67 a year ago. For the current quarter, Edwards Lifesciences is expected to post earnings of $0.73 per share, indicating a change of +9% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days. The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Edwards Lifesciences. Also, the stock has a VGM Score of C. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pacific Biosciences of California, Inc. (PACB) : Free Stock Analysis Report Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

PacBio’s second quarter was met with a negative market reaction, as sales and adjusted earnings per share both fell short of Wall Street’s expectations. Management attributed the underperformance to ongoing funding constraints in the U.S. academic and government sectors, as well as a transition period as customers validated the new SPRQ-Nx chemistry. CEO Mark Van Oene, newly appointed after Christian Henry’s departure, stated that “customer enthusiasm for SPRQ-Nx has remained strong since full launch,” but acknowledged that the pace of adoption and inventory dynamics weighed on quarterly results. Is now the time to buy PACB? Find out in our full research report (it’s free). Revenue: $39.01 million vs analyst estimates of $39.91 million (1.9% year-on-year decline, 2.3% miss) Adjusted EPS: -$0.14 vs analyst expectations of -$0.13 (10.4% miss) Operating Margin: -114%, down from -113% in the same quarter last year Market Capitalization: $354.3 million While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Kyle Mikson (Canaccord Genuity) asked whether most new Revio and Vega system placements were to clinical customers. CEO Mark Van Oene explained that the majority were clinical accounts, highlighting ongoing momentum in clinical adoption for both instruments. Thomas VonDerVellen (Guggenheim) inquired about expected consumables pull-through for the second half as population-scale and clinical customers ramp. Van Oene detailed that consumables revenue would likely remain flat in the next quarter, with growth expected as SPRQ-Nx adoption accelerates later in the year. Jack Meehan (Operon Research) questioned gross margin headwinds related to memory supply and when improvements from multi-use SMRT Cells would be realized. CFO James Gibson clarified that memory costs will persist into 2027, with margin benefits from SPRQ-Nx expected to ramp as adoption increases. Mason Carrico (Stephens) asked if the SPRQ-Nx cost reduction would lead to higher sample volumes to offset lower pricing. Van Oene responded that customer demand and project scale should close the revenue gap as adoption ramps in the back half of the year. Lauren Timmins (Jefferies) probed why full-year guidance was lowered despite positive SPRQ-Nx signals. Van Oene explained that ongoing transition headwinds and elevated compute costs warranted a more cautious outlook. In coming quarters, the StockStory team will closely monitor (1) the pace of SPRQ-Nx adoption and its impact on consumables growth, (2) progress in clinical and population-scale project expansion, particularly in EMEA and new customer segments, and (3) the company’s success in mitigating supply chain and manufacturing cost pressures. Operational execution in driving clinical engagement and expanding gross margins will also be key signposts for PacBio’s path forward. PacBio currently trades at $1.16, down from $1.30 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free for active Edge members). ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time. Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE. Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.

Interested in Pacific Biosciences of California, Inc.? Here are five stocks we like better. Leadership and outlook changed: CEO Christian Henry stepped down and was replaced immediately by Mark Van Oene. PacBio lowered its 2026 revenue forecast to $155 million–$165 million and pushed expected cash-flow breakeven to 2028. Q2 revenue was essentially flat at $39 million: Consumables revenue grew 6% to $20.1 million, but instrument revenue fell 9% to $12.8 million amid fewer Vega shipments and a lower average selling price. SMRT Next adoption is central to the growth strategy: The new multi-use chemistry lowers the cost of a 20x HiFi human genome by 30%, but customer validation and existing reagent inventories are delaying the expected consumables ramp until late 2026. Deciphering Disruption: Inside Cathie Wood's Latest Plays Pacific Biosciences of California (NASDAQ:PACB) reported second-quarter 2026 revenue of $39 million, roughly flat from $39.8 million a year earlier, while announcing an immediate leadership transition and lowering its full-year revenue outlook amid a slower-than-expected rollout of its new multi-use sequencing chemistry and continued funding constraints in academic and government markets. Christian Henry stepped down as president and chief executive officer and will remain on PacBio’s board while serving as an advisor. Mark Van Oene, who previously led the company’s R&D operations and commercial organization, succeeded Henry as president and CEO effective immediately. → SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control Strategic Buy Lights Up This Biotech Stock: Time to Invest? “My priorities will be directly built on this foundation,” Van Oene said, citing plans to scale the company’s clinical-market approach globally, expand adoption of its SMRT Next chemistry and support larger sequencing projects. Consumables revenue rose 6% year over year to $20.1 million, supported by growth in PacBio’s installed base and clinical customer utilization. Shipments to clinical customers increased 67% from the prior-year period and represented a mid-teens percentage of total consumables shipments, according to Van Oene. → 3 Drone Stocks That Should Soar After the Summer Slump Instrument revenue declined 9% to $12.8 million. Chief Financial Officer Jim Gibson said the decrease reflected a lower average selling price resulting from customer mix, including lower-priced strategic Revio placements, as well as fewer Vega system shipments. PacBio sold 20 Revio systems during the quarter, compared with 15 a year earlier. It sold 26 Vega systems, compared with 38 in the prior-year quarter. Cumulative shipments reached 366 Revio systems and 200 Vega systems. Sixty percent of second-quarter Revio placements went to new customers, while 45% were part of multi-instrument orders. Eighty-one percent of Vega shipments went to new customers. Van Oene said the majority of Revio placements during the quarter were to clinical accounts. He also said PacBio is seeing public health laboratories adopt Vega systems, including for wastewater testing and other applications outside traditional high-throughput whole-genome sequencing. → The Bitcoin Comeback May Already Be Underway—2 ETFs for Exposure Regional performance was mixed. Revenue in Europe, the Middle East and Africa increased 52% to $14.4 million, driven by clinical customers moving from pilot programs into routine production, growing Vega demand and a strategic multi-system Revio placement for a national genomics initiative. Americas revenue was $17.6 million, down slightly year over year, as uncertainty around NIH and broader academic funding affected capital purchases. Asia-Pacific revenue declined 45% to $7 million, reflecting the completion of a population sequencing program, funding headwinds and lower consumables demand during customer workflow validation. The company highlighted the global rollout of its SPRQ-Nx, or SMRT Next, chemistry for Revio. The chemistry allows customers to use each SMRT Cell up to three times, increases throughput per run and lowers the U.S. list price of a 20x HiFi human genome to $345, a 30% reduction from PacBio’s prior Spark chemistry, Van Oene said. More than one-third of PacBio’s installed base adopted software supporting the new workflow in June. The company expects more than half of its installed base to opt in by the end of the third quarter and the vast majority by year-end. Customers are currently validating the multi-use workflow and working through existing reagent inventories, leading PacBio to expect consumables growth to gain momentum later in 2026. Van Oene said PacBio expects the SPRQ-Nx transition to continue through the third quarter, with consumables usage beginning to scale toward the end of the year. The company also plans to launch SPRQ-Nx chemistry for Vega in late August, increasing output to up to 90 gigabases per run while reducing DNA input requirements. PacBio cited recent publications supporting long-read sequencing in clinical diagnostics. Van Oene said a June 13 article in The New England Journal of Medicine reported 96.4% concordance between long-read genome sequencing and standard-of-care testing in rare disease diagnostics. In the study, long-read sequencing improved or refined diagnoses in 3.4% of cases, while standard testing identified variants missed by long reads in 0.2% of cases. The company also referenced a Nature Genetics article discussing “near-perfect genome sequencing” and a preprint from the HiFi Solves Sub-fertility Consortium in Asia-Pacific. PacBio said those findings reinforce its view that long-read sequencing can support a broader shift toward a single, more comprehensive testing workflow. Second-quarter non-GAAP gross margin was 36%, down from 38% a year earlier. Gibson attributed the decline to compute cost inflation, lower manufacturing volumes and $1.1 million in costs related to moving Vega manufacturing in-house. PacBio expects Vega manufacturing transition costs to conclude by the end of 2026. Non-GAAP operating expenses declined 3% to $56.1 million. The company reported a non-GAAP net loss of $41.9 million, or $0.14 per share, compared with a loss of $40 million, or $0.13 per share, in the prior-year quarter. PacBio ended the quarter with approximately $236.9 million in unrestricted cash equivalents and investments, down from $279.5 million at the end of 2025. The company recently initiated a reorganization that will reduce its workforce by about 40 employees. Van Oene said the changes integrate marketing more closely with the commercial organization, particularly around clinical customers, while reducing management layers. He said key R&D platform projects were not affected. For 2026, PacBio reduced its revenue outlook to $155 million to $165 million. It now expects non-GAAP gross margin of 35% to 37%, non-GAAP operating expenses of $215 million to $220 million and year-end cash of approximately $175 million to $185 million. Gibson said the company expects the restructuring to reduce 2027 compensation and related expenses by approximately $15 million to $20 million. PacBio also expects another $15 million to $20 million of annual savings after it moves beyond development spending on its high-throughput platform. However, the company now expects to reach cash-flow breakeven in 2028, compared with its previous expectation of the end of 2027. Pacific Biosciences of California, Inc develops, manufactures and sells high-performance DNA sequencing systems for genetic and genomic analysis. The company's proprietary single-molecule, real-time (SMRT) sequencing technology is designed to enable long-read sequencing, offering high accuracy for applications such as de novo genome assembly, transcriptome characterization and structural variation analysis. Pacific Biosciences markets a suite of instruments, including the Sequel and Sequel IIe systems, alongside reagents, consumables and data analysis software to support a range of life science research. Founded in 2004 and headquartered in Menlo Park, California, Pacific Biosciences has expanded its global reach by serving academic institutions, biotechnology and pharmaceutical companies, and government research centers across North America, Europe and Asia. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Pacific Biosciences of California Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for August 2026.

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, reported an adjusted loss per share of 14 cents for the second quarter of 2026, wider than the year-ago adjusted loss of 13 cents per share. The figure came in line with the Zacks Consensus Estimate. The company’s GAAP loss per share was 14 cents in the quarter, flat year over year. PacBio registered total revenues of $39 million, down 2% year over year. The figure missed the Zacks Consensus Estimate by 4.2%. Consumables growth and higher Revio placements were offset by weaker instrument sales and a sharp revenue decline in Asia Pacific. Shares of the company lost around 1.5% during yesterday’s after-hours trading. Year to date, the stock has declined 30.5% compared with the industry’s fall of 10%. However, the broader S&P 500 Index has increased 12.8% in the same time frame. Image Source: Zacks Investment Research Americas revenues were $17.6 million, down 0.6% year over year. Continued uncertainty surrounding NIH, academic and government funding weighed on capital purchasing, though clinical and commercial customer activity remained resilient. Asia-Pacific revenues totaled $7 million, down 45% year over year. The decrease reflected the completion of a significant population-sequencing program, weaker academic and government demand and lower consumables purchases as customers prepared for the SPRQ-Nx transition. EMEA revenues increased 52% year over year to $14.4 million. Growth was driven by clinical customers moving from pilot programs into routine production, stronger Vega demand and a strategic multi-system Revio placement supporting a national genomics initiative. In the quarter under review, total Product revenues amounted to $32.9 million, down 0.4% from the year-ago quarter. Within the Product segment, Instrument revenues were $12.8 million, down 9.9% year over year. The decline reflected a lower average selling price, including strategic Revio placements at key accounts, and fewer Vega shipments amid academic and government funding constraints. Instrument revenues in the quarter included 20 Revio sequencing systems and 26 Vega sequencing systems. PACB ended the quarter with 366 cumulative Revio system shipments and 200 cumulative Vega system shipments. Consumables revenues for the quarter were $20.1 million, up 6.3% from the prior-year quarter, supported by installed-base expansion and continued Revio utilization. Shipments to clinical customers increased 67% and represented a mid-teens percentage of total consumables shipments. Annualized Revio pull-through per system was approximately $202,000 in the quarter. Growth was partly tempered by customers using existing inventory and validating workflows ahead of broader SPRQ-Nx adoption. Service and other revenues totaled $6.1 million, down 9.4% year over year. In the quarter under review, PacBio’s adjusted gross profit decreased 8.3% year over year to $13.9 million. The adjusted gross margin contracted 200 basis points to 36%. Sales, general and administrative expenses declined 7.7% year over year to $33.4 million. Research and development expenses increased 2.2% year over year to $23 million. Adjusted total operating expenses of $56.1 million decreased 3.4% year over year. Total operating loss was $44.6 million in the reported quarter compared with the prior-year quarter’s $44.9 million. PacBio exited the second quarter of 2026 with cash and investments of $236.9 million compared with $275.9 million at the end of the first quarter of 2026. PacBio reduced its 2026 revenue guidance to $155-$165 million from the prior range of $165-$175 million. The Zacks Consensus Estimate is pegged at $165.8 million. The company now expects an adjusted gross margin of 35%-37%. Adjusted operating expenses are projected at $215-$220 million, down $5 million from the previous guidance range. Pacific Biosciences of California, Inc. price-consensus-eps-surprise-chart | Pacific Biosciences of California, Inc. Quote PacBio exited the second quarter of 2026 with mixed results, wherein adjusted earnings met the Zacks Consensus Estimate while revenues missed the same. Growth in consumables revenues, strong clinical demand and an increase in EMEA revenues were encouraging. Gains were partly offset by softer instrument revenues, funding constraints in the Americas and a sharp revenue decline in Asia Pacific. PacBio advanced the global commercial rollout of SPRQ-Nx chemistry, which lowers the U.S. list price of a HiFi whole genome to $345 through multi-use SMRT Cells. The chemistry enhances methylation detection and incorporates DeepConsensus, an AI-powered algorithm co-developed with Google. More than one-third of the installed base had opted for SPRQ-Nx by June, while the company will launch SPRQ-Nx on the Vega platform in August to expand throughput to 90 gigabases per run. Commercial momentum included multi-system Revio orders, a new population-scale customer and continued sample delivery for Basecamp Research. PacBio gained scientific validation through publications in the New England Journal of Medicine and Nature Genetics, along with a HiFi Solves subfertility preprint. The company’s growth strategy centers on replicating EMEA’s clinical success globally, expanding population-scale sequencing and operating with a leaner cost structure. However, PacBio continues to face funding-related weakness in the Americas and Asia-Pacific, slower-than-expected SPRQ-Nx adoption as customers complete workflow validation and cost pressures from memory, compute and Vega manufacturing transition. These factors prompted the company to lower its 2026 revenue and gross margin guidance while pushing its cash flow breakeven target to 2028. PacBio currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are West Pharmaceutical WST, McKesson MCK and Cardinal Health CAH, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here. West Pharmaceutical reported second-quarter 2026 adjusted earnings per share (EPS) of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%. West Pharmaceutical has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%. McKesson reported a first-quarter fiscal 2027 adjusted EPS of $9.93, which beat the Zacks Consensus Estimate by 5.2%. Revenues of $105.4 billion surpassed the Zacks Consensus Estimate by 0.95%. McKesson has an estimated long-term earnings growth rate of 13.7%. MCK’s earnings surpassed estimates in the trailing four quarters, the average surprise being 4.3%. Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%. Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pacific Biosciences of California, Inc. (PACB) : Free Stock Analysis Report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report McKesson Corporation (MCK) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Genomics company Pacific Biosciences of California (NASDAQ:PACB) fell short of the market’s revenue expectations in Q2 CY2026, with sales falling 1.9% year on year to $39.01 million. Its non-GAAP loss of $0.14 per share was 10.4% below analysts’ consensus estimates. Is now the time to buy PacBio? Find out in our full research report. Revenue: $39.01 million vs analyst estimates of $39.91 million (1.9% year-on-year decline, 2.3% miss) Adjusted EPS: -$0.14 vs analyst expectations of -$0.13 (10.4% miss) Operating Margin: -114%, down from -113% in the same quarter last year Market Capitalization: $447.3 million Pioneering what scientists call "HiFi long-read sequencing," recognized as Nature Methods' method of the year for 2022, Pacific Biosciences (NASDAQ:PACB) develops advanced DNA sequencing systems that enable scientists and researchers to analyze genomes with unprecedented accuracy and completeness. Reviewing a company’s long-term sales performance reveals insights into its quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Thankfully, PacBio’s 8.5% annualized revenue growth over the last five years was decent. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. PacBio’s recent performance marks a sharp pivot from its five-year trend as its revenue has shown annualized declines of 8.2% over the last two years. This quarter, PacBio missed Wall Street’s estimates and reported a rather uninspiring 1.9% year-on-year revenue decline, generating $39.01 million of revenue. Looking ahead, sell-side analysts expect revenue to grow 14.2% over the next 12 months, an improvement versus the last two years. This projection is healthy and implies its newer products and services will fuel better top-line performance. ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all. Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE. PacBio’s high expenses have contributed to an average adjusted operating margin of negative 151% over the last five years. Unprofitable healthcare companies require extra attention because they could get caught swimming naked when the tide goes out. It’s hard to trust that the business can endure a full cycle. On the plus side, PacBio’s adjusted operating margin rose by 86.4 percentage points over the last five years, as its sales growth gave it operating leverage. Zooming in on its more recent performance, we can see the company’s trajectory is intact as its margin has also increased by 51.2 percentage points on a two-year basis. PacBio’s adjusted operating margin was negative 114% this quarter. We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable. Although PacBio’s full-year earnings are still negative, it reduced its losses and improved its EPS by 11.6% annually over the last five years. The next few quarters will be critical for assessing its long-term profitability. In Q2, PacBio reported adjusted EPS of negative $0.14, down from negative $0.13 in the same quarter last year. This print missed analysts’ estimates. Over the next 12 months, Wall Street expects PacBio to improve its earnings losses. Analysts forecast its full-year EPS will improve from negative $0.50 to negative $0.48. We struggled to find many positives in these results. Its revenue missed and its EPS fell short of Wall Street’s estimates. Overall, this was a weaker quarter. The stock traded down 1.1% to $1.28 immediately following the results. PacBio may have had a tough quarter, but does that actually create an opportunity to invest right now? If you’re making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it’s free.

MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026. Recent Business Highlights Total revenue of $39.0 million was driven by growing consumables and new Revio and Vega placements as the Company commenced its full rollout of SPRQ-Nx chemistry. Instrument revenue consisted of both single-system and multi-system orders, including an order for several Revio systems from a new population-scale customer Commenced global commercial rollout of SPRQ-Nx, delivering whole genome sequencing at $345 USD list price per genome with enhanced methylation detection and DeepConsensus, an AI-powered consensus algorithm co-developed with Google Commenced sequencing and sample delivery for Basecamp Research, a frontier AI lab for therapeutic design, marking a significant operational milestone for PacBio's largest population-scale program to date Published in a landmark New England Journal of Medicine study, "Clinical Long-Read Genome Sequencing for Rare-Disease Diagnostics." The publication demonstrates that HiFi long-read sequencing is a clinically effective first-tier diagnostic test that improves diagnostic yield while simplifying the laboratory workflow, reducing turnaround time, and enhancing the overall economics of rare disease diagnostics Published in a Nature Genetics article, “Near-perfect genome sequencing in medical genetics.” The publication highlights long-read sequencing as a pillar of near-perfect genome sequencing (NPGS), alongside diploid genome assembly, pangenome references, and AI-driven variant interpretation Contributed to a published preprint from the HiFi Solves Sub-fertility Consortium in Asia Pacific. The preprint demonstrates that PacBio HiFi whole genome sequencing can provide a more complete view of reproductive genetics in one workflow Implemented restructuring actions primarily to streamline marketing and R&D organizations, strengthen the go-to-market commercial organization, and drive greater cost discipline going forward Second quarter results: Gross profit and margin, operating expenses, net loss, and net loss per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the corresponding GAAP measures at the end of this release. GAAP gross profit for the second quarter of 2026 was $12.6 million compared to $14.7 million during the second quarter of 2025. Non-GAAP gross profit for the second quarter of 2026 was $13.9 million compared to $15.2 million for the second quarter of 2025. GAAP gross margin was 32% for the second quarter of 2026 compared to 37% for the second quarter of 2025. Non-GAAP gross margin was 36% for the second quarter of 2026 compared to 38% for the second quarter of 2025. The decline in non-GAAP gross margin was primarily driven by higher compute and memory costs, Vega manufacturing transition costs, and lower Revio average selling prices associated with strategic multi-system customer placements. GAAP operating expenses totaled $57.2 million for the second quarter of 2026 compared to $59.5 million for the second quarter of 2025. Non-GAAP operating expenses totaled $56.1 million for the second quarter of 2026 compared to $58.1 million for the second quarter of 2025. GAAP and non-GAAP operating expenses for the second quarter of 2026 and the second quarter of 2025 included non-cash share-based compensation of $8.6 million and $11.0 million, respectively. GAAP net loss for the second quarter of 2026 was $44.7 million compared to $41.9 million for the second quarter of 2025. Non-GAAP net loss for the second quarter of 2026 was $41.9 million compared to $40.0 million for the second quarter of 2025. GAAP net loss per share for the second quarter of 2026 was $0.14 compared to $0.14 for the second quarter of 2025. Non-GAAP net loss per share for the second quarter of 2026 was $0.14 compared to $0.13 for the second quarter of 2025. 2026 Financial Outlook PacBio expects revenue for the full year 2026 to be in the range of $155 million to $165 million. Quarterly Conference Call Information Management will host a quarterly conference call today at 4:30 p.m. Eastern Time to review financial results for the second quarter ended June 30, 2026. Investors can access the call by dialing 1-888-349-0136 (or 1-412-317-0459 for international callers) and requesting to join the “PacBio Q2 Earnings Call". The call will be webcast live and available for replay at PacBio's website at https://investor.pacificbiosciences.com. About PacBio PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which primarily consist of our HiFi long-read sequencing systems, address solutions across a broad set of research applications, including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio. PacBio products are provided for Research Use Only. Not for use in diagnostic procedures. Statement regarding use of non‐GAAP financial measures PacBio reports non‐GAAP results for basic net income (loss) per share, net income (loss), gross margins, gross profit (loss) and operating expenses in addition to, and not as a substitute for, or because it believes that such information is superior to, financial measures calculated in accordance with GAAP. PacBio believes that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of PacBio’s non-GAAP financial measures as tools for comparison. PacBio's financial measures under GAAP include substantial charges that are listed in the itemized reconciliations between GAAP and non‐GAAP financial measures included in this press release. PacBio excludes recurring charges from its non-GAAP financial statements, including amortization of acquired intangible assets and changes in fair value of contingent consideration, and further excludes infrequent and limited charges including impairment charges, restructuring-related expenses for discrete restructuring events, settlement charges, disposition of short-read assets, benefits from income taxes and other adjustments and rounding differences. Management has excluded the effects of these items in non‐GAAP measures to assist investors in analyzing and assessing past and future operating performance. In addition, management uses non-GAAP measures to compare PacBio’s performance relative to forecasts and strategic plans and to benchmark its performance externally against competitors. PacBio encourages investors to carefully consider its results under GAAP, as well as its supplemental non‐GAAP information and the reconciliation between these presentations, to more fully understand its business. A reconciliation of PacBio’s non-GAAP financial measures to their most directly comparable financial measure stated in accordance with GAAP has been provided in the financial statement tables included in this press release. PacBio is unable to reconcile future-looking non-GAAP guidance without unreasonable effort because certain items that impact this measure are out of PacBio's control and/or cannot be reasonably predicted at this time. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including, but not limited to, statements relating to PacBio’s initiatives as well as the expected financial impact and timing of these plans and initiatives, including PacBio's expectations regarding long-read sequencing and SPRQ-Nx; PacBio's expectations regarding its restructuring efforts; PacBio’s financial guidance and expectations for future periods; new and continued reception of PacBio’s products and their expansion into new or existing markets; and the availability, uses, accuracy, coverage, advantages, quality or performance of, or benefits or expected benefits of using, PacBio products or technologies. Reported results and orders for any instrument system should not be considered an indication of future performance. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including, but not limited to, challenges inherent in developing, manufacturing, launching, marketing and selling new products, and achieving anticipated new sales; potential cancellation of existing instrument orders; assumptions, risks and uncertainties related to the ability to attract new customers and retain and grow sales from existing customers; risks related to PacBio's ability to successfully execute and realize the benefits of acquisitions; the impact of new, increased or enhanced tariffs and export restrictions; rapidly changing technologies and extensive competition in genomic sequencing; unanticipated increases in costs or expenses; high costs of computer memory components; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products and products under development; potential product performance and quality issues and potential delays in development timelines; the possible loss of key employees, customers, or suppliers; customers and prospective customers curtailing or suspending activities using PacBio's products; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights; risks associated with international operations; and other risks associated with general macroeconomic conditions and global economic or political instability, including war and other international conflicts, such as the conflicts in the Middle East. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption “Risk Factors.” These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available. The unaudited condensed consolidated financial statements that follow should be read in conjunction with the notes set forth in PacBio's Quarterly Report on Form 10-Q when filed with the Securities and Exchange Commission. Contacts Investors:[email protected] Media:[email protected] (1)  Balances for the three months ended June 30, 2025 include restructuring costs. Refer to the Reconciliation of Non-GAAP Financial Measures table below for additional information on such costs and related amounts. (2)  Balances for the three months ended June 30, 2026 and March 31, 2026 include litigation settlement charges and related legal fees in connection with the agreement entered into with Personal Genomics of Taiwan, Inc. Refer to the Reconciliation of Non-GAAP Financial Measures table below for additional information on such costs and related amounts. (3)  Balances for the three months ended June 30, 2026 and March 31, 2026 include amounts related to the disposition of short-read assets, including the gain on the sale of certain assets related to our short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies, and related non-recurring customer transition costs. Refer to the Reconciliation of Non-GAAP Financial Measures table below for additional information on such costs and related amounts. (4)  Balance for the three months ended June 30, 2026 includes interest expense related to the Personal Genomics of Taiwan, Inc. settlement liability. (1)  Balances for the three and six months ended June 30, 2025 include restructuring costs. Refer to the Reconciliation of Non-GAAP Financial Measures table below for additional information on such costs and related amounts. (2)  In-process research and development ("IPR&D") impairment charge during the six months ended June 30, 2025 was driven primarily by macroeconomic factors and restructuring initiatives, including the focus on long-read innovation, resulting in changes to the timing and amounts of cash flows. (3)  Balances for the three and six months ended June 30, 2026 include litigation settlement charges and related legal fees in connection with the agreement entered into with Personal Genomics of Taiwan, Inc. Refer to the Reconciliation of Non-GAAP Financial Measures table below for additional information on such costs and related amounts. (4)  Balances for the three and six months ended June 30, 2026 include amounts related to the disposition of short-read assets, including the gain on the sale of certain assets related to our short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies, and related non-recurring customer transition costs. Refer to the Reconciliation of Non-GAAP Financial Measures table below for additional information on such costs and related amounts. (5)  Balance for the six months ended June 30, 2025 includes accelerated amortization of acquired intangible assets related to restructuring initiatives. Refer to the Reconciliation of Non-GAAP Financial Measures table below for additional information on such costs and related amounts. (6)  Change in fair value of contingent consideration during the six months ended June 30, 2025 was due to fair value adjustments of milestone payments payable upon the achievement of a milestone event. (1)  Change in fair value of contingent consideration during the six months ended June 30, 2025 was due to fair value adjustments of milestone payments payable upon the achievement of a milestone event. (2)  Balances for the three months ended June 30, 2026 and March 31, 2026 and the six months ended June 30, 2026 include litigation settlement charges and related legal fees in connection with the agreement entered into with Personal Genomics of Taiwan, Inc. (3)  Balances for the three and six months ended June 30, 2026 include amortization of a patent license acquired in connection with the agreement entered into with Personal Genomics of Taiwan, Inc. (4)  Balances for the three months ended June 30, 2026 and March 31, 2026 and the six months ended June 30, 2026 include amounts related to the disposition of short-read assets, including the gain on the sale of certain assets related to our short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies, and related non-recurring customer transition costs. (5)  Interest expense for the three and six months ended June 30, 2026 is related to the liability incurred in connection with the agreement entered into with Personal Genomics of Taiwan, Inc. (6)  A deferred income tax benefit during the six months ended June 30, 2025 is primarily related to the change in the deferred tax liability balance resulting from the accelerated amortization of acquired intangible assets and IPR&D impairment. (7)  Restructuring-related costs incurred in connection with the 2025 plan during the three and six months ended June 30, 2025 consist primarily of costs included in cost of revenue related to excess inventory and purchase commitment losses, as well as costs included in operating expenses related to employee separation, accelerated depreciation, IPR&D impairment, and accelerated amortization of acquired intangibles.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Mark Van Oene succeeded Christian Henry as CEO, signaling a shift toward scaling clinical engagement strategies globally following successful execution in the EMEA region. Initiated a targeted reorganization to integrate marketing more closely with commercial operations, focusing on clinical market growth while reducing management layers. Launched SPRQ-Nx chemistry globally, which reduces the cost per human genome by 30% to $345 by allowing SMRT Cells to be reused up to three times. Performance was driven by a 67% year-over-year increase in consumable shipments to clinical customers, which now represent a mid-teens percentage of total shipments. Revio instrument placements rebounded to 20 units, supported by multi-system orders from customers expanding fleets for larger population-scale genomic studies. Vega system demand remains constrained by U.S. academic and government funding uncertainty, though ASPs have normalized following the conclusion of Q1 promotional pricing. Management attributes the flat year-over-year revenue to customers working through existing inventory while validating the new multi-use SPRQ-Nx workflows. Lowered 2026 revenue guidance to $155 million to $165 million, assuming a more gradual recovery in China and persistent funding constraints in the Americas. Extended the timeline for cash flow breakeven to 2028, citing elevated compute and memory costs and a slower gross margin improvement trajectory. Expects SPRQ-Nx to be a significant volume driver in the second half of 2026 as over half the installed base is projected to adopt the new software by the end of Q3. Anticipates 2027 cash burn to step down meaningfully due to $15 million to $20 million in restructuring savings, plus an additional $15 million to $20 million in savings from the conclusion of development spending on the high-throughput platform. Plans to launch SPRQ-Nx chemistry on the Vega system in August 2026 to harmonize throughput and DNA input requirements across the instrument portfolio. Restructuring involves a workforce reduction of approximately 40 employees to align the cost structure with clinical growth priorities. Gross margins were impacted by $1.1 million in temporary costs related to transitioning Vega manufacturing in-house, a process expected to conclude by year-end 2026. Strategic pre-purchasing of memory components has secured supply through the end of 2026, though spot market fluctuations remain a persistent headwind. Revised Revio pull-through guidance to $200,000 to $225,000 per system to reflect the current pace of demand and inventory burn-down during the chemistry transition. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Management confirmed the majority of Revio placements are going to clinical accounts, while Vega is successfully attracting new-to-PacBio customers. Public health labs are beginning to adopt Vega for non-traditional applications like wastewater testing and higher-throughput whole genome sequencing. Supply for memory and GPUs is locked in through the end of 2026, but management lacks clear visibility into 2027 pricing dynamics. The 35% to 37% gross margin guidance accounts for persistent compute cost inflation and the temporary costs of insourcing Vega manufacturing. Management expects the 30% price reduction per genome to be offset by increased sample volumes as the technology becomes economically viable for larger projects. Early indicators in Asia-Pacific show customers are actively burning through old inventory to transition to the higher-throughput SPRQ-Nx chemistry. The restructure aims to replicate the EMEA clinical success model globally by uniting marketing and sales motions specifically around clinical workflows. Management clarified that large-scale biopharma and AI data deals will continue to be managed through business development, separate from the clinical sales focus.

Looking back on life sciences tools & services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including PacBio (NASDAQ:PACB) and its peers. The life sciences tools and services sector supports biotech and pharmaceutical R&D and commercialization by providing lab equipment, data analytics, and clinical trial services. These companies benefit from recurring revenue and high margins on specialized products. Looking ahead, the sector is supported by tailwinds like advancements in genomics, personalized medicine, and the use of AI in drug discovery. However, the persistent challenge is dependence on the R&D budgets of large pharmaceutical companies and the volatility of smaller biotech firms. Future headwinds include uncertain research funding and pricing pressures from cost-conscious customers. The 21 life sciences tools & services stocks we track reported a satisfactory Q1. As a group, revenues beat analysts’ consensus estimates by 1.2% while next quarter’s revenue guidance was in line. Luckily, life sciences tools & services stocks have performed well with share prices up 10.2% on average since the latest earnings results. Pioneering what scientists call "HiFi long-read sequencing," recognized as Nature Methods' method of the year for 2022, Pacific Biosciences (NASDAQ:PACB) develops advanced DNA sequencing systems that enable scientists and researchers to analyze genomes with unprecedented accuracy and completeness. PacBio reported revenues of $37.18 million, flat year on year. This print fell short of analysts’ expectations by 7.1%. Overall, it was a softer quarter for the company with a significant miss of analysts’ revenue estimates. “We continue to see increasing clinical adoption of HiFi which contributed to another record quarter for consumable revenue. However, instrument revenue, particularly Vega, was lower than we had expected," said Christian Henry, President and Chief Executive Officer. PacBio delivered the weakest performance against analyst estimates of the whole group. Unsurprisingly, the stock is down 6.4% since reporting and currently trades at $1.55. Read our full report on PacBio here, it’s free. Founded in 1923 and serving as a critical link in the pharmaceutical supply chain, West Pharmaceutical Services (NYSE:WST) manufactures specialized packaging, containment systems, and delivery devices for injectable drugs and healthcare products. West Pharmaceutical Services reported revenues of $844.9 million, up 21% year on year, outperforming analysts’ expectations by 8.4%. The business had a stunning quarter with a beat of analysts’ EPS and revenue estimates. West Pharmaceutical Services achieved the biggest analyst estimate beat among its peers. The market seems happy with the results as the stock is up 18% since reporting. It currently trades at $323.85. Is now the time to buy West Pharmaceutical Services? Access our full analysis of the earnings results here, it’s free. Serving as the guardian of some of medicine's most valuable materials, Azenta (NASDAQ:AZTA) provides biological sample management, storage, and genomic services that help pharmaceutical and biotechnology companies preserve and analyze critical research materials. Azenta reported revenues of $144.8 million, up 1% year on year, falling short of analysts’ expectations by 2.5%. It was a disappointing quarter as it posted a significant miss of analysts’ revenue and EPS estimates. As expected, the stock is down 5.8% since the results and currently trades at $23.19. Read our full analysis of Azenta’s results here. With roots dating back to the pioneering days of nuclear magnetic resonance technology, Bruker (NASDAQ:BRKR) develops and manufactures high-performance scientific instruments that enable researchers and industrial analysts to explore materials at microscopic, molecular, and cellular levels. Bruker reported revenues of $823.4 million, up 2.7% year on year. This number beat analysts’ expectations by 3.4%. Overall, it was a very strong quarter as it also put up a beat of analysts’ EPS and revenue estimates. The stock is up 56% since reporting and currently trades at $59.30. Read our full, actionable report on Bruker here, it’s free. Pioneering the ability to read the human genome at unprecedented speed and affordability, Illumina (NASDAQ:ILMN) develops and sells advanced DNA sequencing and microarray technologies that allow researchers and clinicians to analyze genetic variations and functions. Illumina reported revenues of $1.09 billion, up 4.8% year on year. This result topped analysts’ expectations by 1.8%. It was a strong quarter as it also produced a solid beat of analysts’ full-year EPS guidance estimates. The stock is up 29.1% since reporting and currently trades at $163.68. Read our full, actionable report on Illumina here, it’s free. Late in 2025 into early 2026, there was hand-wringing around artificial intelligence. For software companies, the fear was that AI would erode pricing power and compress margins as new tools made it easier to replicate what once required expensive enterprise platforms. Crypto investors had their own version of the same anxiety: if AI agents could trade, allocate capital, and manage wallets autonomously, what exactly was the long-term value of today’s crypto infrastructure? These concerns triggered a noticeable rotation away from these sectors and into safer havens. But markets rarely dwell on one narrative for long. Spring 2026 came, and the focus shifted abruptly from technological disruption to geopolitical risk. The US’ conflict with Iran became the dominant driver of market psychology, and when geopolitics takes center stage, the script changes quickly. Investors stop debating growth rates and start worrying about oil supply, inflation, and global stability. Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Growth Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. StockStory’s analyst team — all seasoned professional investors — uses quantitative analysis and automation to deliver market-beating insights faster and with higher quality.